212 related articles for article (PubMed ID: 35574218)
61. Myeloproliferative disorders with t(8;9)(p12;q33): a case report and review of the literature.
Hu S; He Y; Zhu X; Li J; He H
Pediatr Hematol Oncol; 2011 Mar; 28(2):140-6. PubMed ID: 21214407
[TBL] [Abstract][Full Text] [Related]
62. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.
Million RP; Van Etten RA
Blood; 2000 Jul; 96(2):664-70. PubMed ID: 10887132
[TBL] [Abstract][Full Text] [Related]
63. Myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Strati P; Tang G; Duose DY; Mallampati S; Luthra R; Patel KP; Hussaini M; Mirza AS; Komrokji RS; Oh S; Mascarenhas J; Najfeld V; Subbiah V; Kantarjian H; Garcia-Manero G; Verstovsek S; Daver N
Leuk Lymphoma; 2018 Jul; 59(7):1672-1676. PubMed ID: 29119847
[TBL] [Abstract][Full Text] [Related]
64. Myeloid and lymphoid neoplasm with abnormalities of FGFR1 presenting with trilineage blasts and RUNX1 rearrangement: a case report and review of literature.
Kumar KR; Chen W; Koduru PR; Luu HS
Am J Clin Pathol; 2015 May; 143(5):738-48. PubMed ID: 25873510
[TBL] [Abstract][Full Text] [Related]
65. Prevalence of chromosome 8p11.2 translocations and correlation with myeloid and lymphoid neoplasms associated with FGFR1 abnormalities in a consecutive cohort from nine institutions in Japan.
Usuki K; Kameda T; Kawano N; Ito T; Hashimoto Y; Shide K; Kawano H; Sekine M; Toyama T; Iizuka H; Sato S; Takeuchi M; Ishizaki J; Maeda K; Nakai M; Yamashita K; Kubuki Y; Shimoda K
Int J Hematol; 2024 Jun; 119(6):722-727. PubMed ID: 38457113
[TBL] [Abstract][Full Text] [Related]
66. A ZMYM2-FGFR1 8p11 myeloproliferative neoplasm with a novel nonsense RUNX1 mutation and tumor lysis upon imatinib treatment.
Buijs A; van Wijnen M; van den Blink D; van Gijn M; Klein SK
Cancer Genet; 2013 Apr; 206(4):140-4. PubMed ID: 23751892
[TBL] [Abstract][Full Text] [Related]
67. Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement.
Loscocco GG; Ascani S; Mannelli F; Zanelli M; Rotunno G; Santi R; Vannucchi AM
Am J Hematol; 2023 Dec; 98(12):1959-1962. PubMed ID: 37435901
[No Abstract] [Full Text] [Related]
68. Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/
Manur R; Sung PJ; Loren AW; Ritchie EK; Frank D; Bagg A; Geyer JT; Bogusz AM
Leuk Lymphoma; 2020 Feb; 61(2):450-454. PubMed ID: 31524018
[No Abstract] [Full Text] [Related]
69. [8p11 myeloproliferative syndrome with CEP110-FGFR1 fusion in a patient].
Chao H; Chen S; Zhou M; Lu X; Zhang X; Pan J; Wu C; Zhang R
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Oct; 32(5):679-82. PubMed ID: 26418991
[TBL] [Abstract][Full Text] [Related]
70. Fine-needle aspiration cytology of T-lymphoblastic lymphoma associated FGFR1 rearrangement myeloproliferative neoplasm.
Patel RA; Sheehan AM; Finch CJ; Lopez-Terrada D; Hernandez VS; Curry CV
Diagn Cytopathol; 2014 Jan; 42(1):45-8. PubMed ID: 23904402
[TBL] [Abstract][Full Text] [Related]
71. Fibroblast growth factor receptor 1 (FGFR1) tyrosine phosphorylation regulates binding of FGFR substrate 2alpha (FRS2alpha) but not FRS2 to the receptor.
Zhang Y; McKeehan K; Lin Y; Zhang J; Wang F
Mol Endocrinol; 2008 Jan; 22(1):167-75. PubMed ID: 17901128
[TBL] [Abstract][Full Text] [Related]
72. The 8p11 myeloproliferative syndrome owing to rare FGFR1OP2-FGFR1 fusion.
Onozawa M; Ohmura K; Ibata M; Iwasaki J; Okada K; Kasahara I; Yamaguchi K; Kubota K; Fujisawa S; Shigematsu A; Endo T; Kondo T; Hashino S; Tanaka J; Matsuno Y; Asaka M; Imamura M
Eur J Haematol; 2011 Apr; 86(4):347-9. PubMed ID: 21198859
[No Abstract] [Full Text] [Related]
73. Rapid transformation of atypical myeloproliferative disorder with consistent t(8;13) to B-cell acute lymphoblastic leukemia: a case report.
Sahin F; Sercan Z; Ertan Y; Ocakci S; Ay E; Vural F; Yuksel E; Tombuloglu M; Saydam G
Hematology; 2007 Dec; 12(6):489-92. PubMed ID: 17852454
[TBL] [Abstract][Full Text] [Related]
74. 8p11 myeloproliferative syndrome with t(1;8)(q25;p11.2): a case report and review of the literature.
Kim WS; Park SG; Park G; Jang SJ; Moon DS; Kang SH
Acta Haematol; 2015; 133(1):101-5. PubMed ID: 25227135
[TBL] [Abstract][Full Text] [Related]
75. Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: report of a new case and review of the literature.
Mozziconacci MJ; Carbuccia N; Prebet T; Charbonnier A; Murati A; Vey N; Chaffanet M; Birnbaum D
Leuk Res; 2008 Aug; 32(8):1304-8. PubMed ID: 18096225
[TBL] [Abstract][Full Text] [Related]
76. Loss of the BCR-FGFR1 GEF Domain Suppresses RHOA Activation and Enhances B-Lymphomagenesis in Mice.
Hu T; Chong Y; Lu S; Qin H; Ren M; Savage NM; Chang CS; Cowell JK
Cancer Res; 2019 Jan; 79(1):114-124. PubMed ID: 30413411
[TBL] [Abstract][Full Text] [Related]
77. A biphenotypic transformation of 8p11 myeloproliferative syndrome with CEP1/FGFR1 fusion gene.
Yamamoto K; Kawano H; Nishikawa S; Yakushijin K; Okamura A; Matsui T
Eur J Haematol; 2006 Oct; 77(4):349-54. PubMed ID: 16879608
[TBL] [Abstract][Full Text] [Related]
78. FGFR1 translocation with concurrent myeloproliferative neoplasm, systemic mastocytosis, and lymphoblastic lymphoma: a case report.
Chang K; Liu JH; Yu SC; Lin CW
Hum Pathol; 2018 Apr; 74():114-121. PubMed ID: 29107667
[TBL] [Abstract][Full Text] [Related]
79. Pemigatinib for the treatment of myeloid/lymphoid neoplasms with
Freyer CW; Hughes ME; Carulli A; Bagg A; Hexner E
Expert Rev Anticancer Ther; 2023 Apr; 23(4):351-359. PubMed ID: 36927350
[TBL] [Abstract][Full Text] [Related]
80. [The 8p11 myeloproliferative syndrome].
Reither A; Hehlmann R; Goldman JM; Cross NC
Med Klin (Munich); 1999 Apr; 94(4):207-10. PubMed ID: 10373756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
